Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab

Per Soelberg Sørensen; Poul Erik Hyldgaard Jensen; Aiden Haghikia; Malin Lundkvist; Christian Vedeler; Finn Sellebjerg; Nils Koch-Henriksen; Anna Fogdell-Hahn; Kjell-Morten Myhr; Jan Hillert; Ralf Gold

doi:10.1177/1352458511404271

Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab

Per Soelberg Sørensen, Poul Erik Hyldgaard Jensen, Aiden Haghikia, Malin Lundkvist, Christian Vedeler, Finn Sellebjerg, Nils Koch-Henriksen, Anna Fogdell-Hahn, Kjell-Morten Myhr, Jan Hillert, Ralf Gold

Department of Neurology

54 Citations (Scopus)

Abstract

In the clinical trials about 9% of natalizumab treated multiple sclerosis (MS) patients generated anti-natalizumab antibodies, of which 6% were persistent and 3% transient. The occurrence of antibodies reduced serum levels of natalizumab, decreased bio-efficacy, and abrogated the therapeutic efficacy.

Original language	English
Journal	Multiple Sclerosis
Volume	17
Issue number	9
Pages (from-to)	1074-8
Number of pages	5
ISSN	1352-4585
DOIs	https://doi.org/10.1177/1352458511404271
Publication status	Published - 2011

Keywords

Adolescent
Adult
Aged
Antibodies, Anti-Idiotypic
Antibodies, Monoclonal, Humanized
Female
Humans
Integrin alpha4
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting

Access to Document

10.1177/1352458511404271

Cite this

@article{22a85ca5fe374aa19f683b0212c2a983,

title = "Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab",

abstract = "In the clinical trials about 9\% of natalizumab treated multiple sclerosis (MS) patients generated anti-natalizumab antibodies, of which 6\% were persistent and 3\% transient. The occurrence of antibodies reduced serum levels of natalizumab, decreased bio-efficacy, and abrogated the therapeutic efficacy.",

keywords = "Adolescent, Adult, Aged, Antibodies, Anti-Idiotypic, Antibodies, Monoclonal, Humanized, Female, Humans, Integrin alpha4, Male, Middle Aged, Multiple Sclerosis, Relapsing-Remitting",

author = "S{\o}rensen, \{Per Soelberg\} and Jensen, \{Poul Erik Hyldgaard\} and Aiden Haghikia and Malin Lundkvist and Christian Vedeler and Finn Sellebjerg and Nils Koch-Henriksen and Anna Fogdell-Hahn and Kjell-Morten Myhr and Jan Hillert and Ralf Gold",

year = "2011",

doi = "10.1177/1352458511404271",

language = "English",

volume = "17",

pages = "1074--8",

journal = "Multiple Sclerosis",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "9",

}

TY - JOUR

T1 - Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab

AU - Sørensen, Per Soelberg

AU - Jensen, Poul Erik Hyldgaard

AU - Haghikia, Aiden

AU - Lundkvist, Malin

AU - Vedeler, Christian

AU - Sellebjerg, Finn

AU - Koch-Henriksen, Nils

AU - Fogdell-Hahn, Anna

AU - Myhr, Kjell-Morten

AU - Hillert, Jan

AU - Gold, Ralf

PY - 2011

Y1 - 2011

N2 - In the clinical trials about 9% of natalizumab treated multiple sclerosis (MS) patients generated anti-natalizumab antibodies, of which 6% were persistent and 3% transient. The occurrence of antibodies reduced serum levels of natalizumab, decreased bio-efficacy, and abrogated the therapeutic efficacy.

AB - In the clinical trials about 9% of natalizumab treated multiple sclerosis (MS) patients generated anti-natalizumab antibodies, of which 6% were persistent and 3% transient. The occurrence of antibodies reduced serum levels of natalizumab, decreased bio-efficacy, and abrogated the therapeutic efficacy.

KW - Adolescent

KW - Adult

KW - Aged

KW - Antibodies, Anti-Idiotypic

KW - Antibodies, Monoclonal, Humanized

KW - Female

KW - Humans

KW - Integrin alpha4

KW - Male

KW - Middle Aged

KW - Multiple Sclerosis, Relapsing-Remitting

UR - https://www.scopus.com/pages/publications/84860396489

U2 - 10.1177/1352458511404271

DO - 10.1177/1352458511404271

M3 - Journal article

C2 - 21511692

SN - 1352-4585

VL - 17

SP - 1074

EP - 1078

JO - Multiple Sclerosis

JF - Multiple Sclerosis

IS - 9

ER -

Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this